How local breast cancer treatments affect side effects and quality of life in Chinese patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PERSEVERE is a prospective, multi-center cohort that follows people with stage I–III breast cancer who are receiving surgery and/or neoadjuvant or adjuvant therapies. Participants complete regular patient-reported outcome questionnaires and undergo clinical checks such as heart imaging, lung function tests, routine labs, and blood and tissue sample collection. The study tracks short- and long-term physical, psychological, and social effects of treatment to map patterns of toxicity and recovery. Data will be used to link clinical tests and biomarkers with reported symptoms and quality-of-life changes over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women aged 18 years or older
* Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology
* No signs of metastatic disease (cancer that has spread to other parts of the body)
* Scheduled to receive local treatment, including:

Surgery

And/or neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy

* Willing and able to complete health questionnaires and attend follow-up visits
* Has given written informed consent to join the study

Exclusion Criteria:

* Have metastatic breast cancer or local recurrence
* Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study
* Are currently pregnant or breastfeeding
* Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer)
* Are unable to participate in the study due to mental, physical, or legal reasons (for example, under legal guardianship or imprisonment)

Where it's running

• National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, Beijing Municipality, China Recruiting
• Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
  Shenzhen, Guangdong, China Active not recruiting
• Shanxi Cancer Hospital
  Taiyuan, Shanxi, China Active not recruiting

Study contacts

• Principal investigator: Yi Fang, MD — National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
• Study coordinator: Zheng Qu, MD
• Email: quzheng1237@gmail.com
• Phone: +8615010998669

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dalpiciclib plus hormone therapy for early HR+/HER2- breast cancer

  This trial tests whether adding dalpiciclib at two different doses and durations to standard hormone therapy helps people with early HR+/HER2- breast cancer.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian and 1 other locations · NCT07581834

• Benchmark and performance test for AI reading breast ultrasound images

  This project will test whether multimodal AI models can read breast ultrasound images to help classify normal, benign, and malignant findings for people who have had breast ultrasound.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07500428

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Understanding breast cancer risk factors and outcomes in Florida

  This study is trying to understand the different risk factors and outcomes of breast cancer in men and women in Florida by collecting samples and survey information from new patients at breast clinics.

  Recruiting at 2 sites Memorial Sloan Kettering Cancer Center · Los Angeles, California and 2 other locations · NCT06780176

• 68Ga-FAPI-46 versus 18F-FDG PET imaging in ER-positive breast cancer

  This test compares whether 68Ga-FAPI-46 PET scans find more cancer spread than standard 18F-FDG PET scans in people with ER-positive breast cancer who need staging.

  Recruiting Phase 2 Maastricht University Medical Center · Maastricht · NCT06335069

• Combination treatment for brain metastasis from ER+/HER-2- breast cancer

  This study is testing a new combination treatment of elacestrant and abemaciclib to see if it can help people with brain metastases from estrogen receptor-positive, HER-2 negative breast cancer.

  Recruiting at 78 sites Phase 1/2 Stemline Therapeutics, Inc. · Fullerton, California and 85 other locations · NCT05386108

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.